Lineage Cell Therapeutics (LCTX) Revenue Growth (1y) (2011 - 2026)
Lineage Cell Therapeutics (LCTX) Revenue Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,071.81 Bn | - | - |
| 2 | Nanobiotix | 1,925.70 Bn | 1,925.64 Bn | - | - |
| 3 | Akari Therapeutics | 1,062.88 Bn | 1,062.88 Bn | - | - |
| 4 | BeOne Medicines | 469.09 Bn | 464.29 Bn | 1.35 Bn | 35.46% |
| 5 | Vertex Pharmaceuticals | 123.09 Bn | 115.84 Bn | 2.59 Bn | 7.82% |
| 6 | Regeneron Pharmaceuticals | 70.32 Bn | 61.57 Bn | 3.31 Bn | 19.04% |
| 7 | Belite Bio | 63.36 Bn | 63.36 Bn | - | - |
| 8 | Argenx Se | 55.90 Bn | 50.71 Bn | 1.41 Bn | 64.03% |
| 9 | Alnylam Pharmaceuticals | 37.69 Bn | 34.68 Bn | 959.66 Mn | 96.43% |
| 10 | Lineage Cell Therapeutics | 252.21 Mn | 189.49 Mn | 1.73 Mn | 14.85% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 14.85% |
| Dec 31, 2025 | 130.40% |
| Sep 30, 2025 | -2.59% |
| Jun 30, 2025 | 96.38% |
| Mar 31, 2025 | 4.02% |
| Dec 31, 2024 | 37.36% |
| Sep 30, 2024 | 203.29% |
| Jun 30, 2024 | -56.34% |
| Mar 31, 2024 | -39.48% |
| Dec 31, 2023 | 9.03% |
| Sep 30, 2023 | -58.44% |
| Jun 30, 2023 | -29.17% |
| Mar 31, 2023 | -54.44% |
| Dec 31, 2022 | -96.17% |
| Sep 30, 2022 | 32.07% |
| Jun 30, 2022 | 789.26% |
| Mar 31, 2022 | 1,239.39% |
| Dec 31, 2021 | 13,984.51% |
| Sep 30, 2021 | 297.55% |
| Jun 30, 2021 | 32.64% |